Lineage Cell Therapeutics, Inc. Common Stock · Cash & Short-Term Investments

Latest reported$55.78Mperiod endingDec 31, 2025

LCTX FY Cash & Short-Term Investments ($4.80M → $55.78M)

Annual Cash & Short-Term Investments

High-resolution chart · PNG

LCTX cash & short-term investments history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Lineage Cell Therapeutics, Inc. Common Stock Cash & Short-Term Investments — Annual fiscal periods (USD)
Period ending	Cash & Short-Term Investments (USD)
Dec 31, 2025	55,781,000
Dec 31, 2024	47,805,000
Dec 31, 2023	35,492,000
Dec 31, 2022	57,875,000
Dec 31, 2021	58,358,000
Dec 31, 2020	41,562,000
Dec 31, 2019	30,716,000
Dec 31, 2018	30,741,000
Dec 31, 2017	38,175,000
Dec 31, 2016	22,715,000
Dec 31, 2015	42,982,000
Dec 31, 2014	29,486,909
Dec 31, 2013	5,495,478
Dec 31, 2012	4,349,967
Dec 31, 2011	22,211,897
Dec 31, 2010	33,324,924
Dec 31, 2009	12,189,081
Dec 31, 2008	12,279
Dec 31, 2007	9,501
Dec 31, 2006	561,017
Dec 31, 2005	1,833,774
Dec 31, 2004	1,370,762
Dec 31, 2003	717,184
Dec 31, 2002	1,284,432
Dec 31, 2001	1,652,748
Dec 31, 2000	1,318,338
Dec 31, 1999	5,292,806
Dec 31, 1998	2,400,000
Jun 30, 1998	6,300,000
Jun 30, 1996	2,400,000
Jun 30, 1995	3,400,000
Jun 30, 1994	700,000
Jun 30, 1993	1,500,000
Jun 30, 1992	4,800,000